Abstracts tagged "Biologic agents"

Abstract Number: 132 • 2016 ACR/ARHP Annual Meeting
Ultrasound Performed Among RA Patients in Real Life Setting Can Predict Loss of Remission, Especially When Done Early after Reaching Remission
Pascal Zufferey¹, Giorgio Tamborrini², Burkhard Moeller³, Adrian Ciurea⁴, Laure Brulhart⁵, Sandra Blumhardt⁶, Martin Toniolo⁷ and Hans Ruedi Ziswiler⁸, ¹Department of Rheumatology, University Hospital Lausanne, Lausanne, Switzerland, ²Bethesda spital, Basel, Switzerland, ³Rheumatology & Clin Immunology, Inselspital Bern, Bern, Switzerland, ⁴Center of Experimental Rheumatology, University Hospital Zurich, Zurich Schlieren, Switzerland, ⁵médecine, hôpital neuchateulois, La chaux de fond, Switzerland, ⁶rheumatology, USZ, zurich, Switzerland, ⁷Department of Rheumatology, University Hospital of Zurich, Zurich, Switzerland, ⁸Osteorheuma, Bern, Switzerland
Background/Purpose: Previous publications have suggested that patients in clinical remission with residual ultrasound (US) synovitis flare more often and do not stay in remission as long…
Abstract Number: 1630 • 2016 ACR/ARHP Annual Meeting
Consistent Pharmacodynamic Effects of Sirukumab, an Anti–IL-6 Cytokine Monoclonal Antibody, on Serum Analytes Across Four Phase 3 Clinical Trials in Rheumatoid Arthritis
Matthew Loza¹, Kristen Sweet¹, Nancy Peffer¹, Carol Franks¹, Keying Ma¹, Kim Campbell¹, Martin Sims² and Bidisha Dasgupta¹, ¹Janssen Research & Development, LLC, Spring House, PA, ²GSK Medicines Research Centre, Stevenage, Hertfordshire, United Kingdom
Background/Purpose: The efficacy of sirukumab, an anti-IL-6 cytokine antibody, was evaluated in multiple phase 3 studies in patients with rheumatoid arthritis (RA) (SIRROUND -M, -D,…
Abstract Number: 2254 • 2016 ACR/ARHP Annual Meeting
Patient Adherence with Biologic Therapy in Rheumatoid Arthritis: A Real-World Review of Compliance
Laurent Chanroux, Fara Mboge and Denise Baldock, Therapy Watch, Research Partnership, London, United Kingdom
Background/Purpose: Biologic agents (bDMARDs) have been shown to help control disease progression in rheumatoid arthritis (RA) and reduce joint damage. The aim of our research…
Abstract Number: 2648 • 2016 ACR/ARHP Annual Meeting
Predictive Role of Biomarkers for the Response to Biologic Therapy in Rheumatoid Arthritis. Old, New and How Future Looks like?
Bogdan Ion Gavrila¹, Claudia Ciofu², Victor Stoica³, Cornel Ursaciuc⁴, Dan Ciotaru⁴, Mihaela Surcel⁵, Adriana Munteanu⁴ and Eugenia Panaitescu⁶, ¹Internal Medicine and Rheumatology, Department of Internal Medicine and Rheumatology Cantacuzino Hospital, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania, Bucharest, Romania, ²Department of Internal Medicine and Rheumatology Cantacuzino Hospital, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania, Bucharest, Romania, ³Carol Davila University of Medicine and Pharmacy, Internal Medicine and Rheumatology Department, Cantacuzino Clinical Hospital, Bucharest, Romania, ⁴INCD ,,Victor Babeș’’, Bucharest, Romania, Bucharest, Romania, ⁵INCD ,,Victor Babeș’’, Bucharest, Romania, bucharest, Romania, ⁶Carol Davila University of Medicine and Pharmacy ,Medical Informatics and Biostatistics, Bucharest, Romania
Background/Purpose: discovery of biomarkers that can identify pretreatment patients who will respond to biologic DMARDs therapy is one of the major interests in RA. We…
Abstract Number: 402 • 2016 ACR/ARHP Annual Meeting
The Risk of Hospitalized Infection Associated with Initiation of Abatacept Versus TNF Inhibitors in Juvenile Idiopathic Arthritis
Timothy Beukelman¹, Fenglong Xie², John Baddley³, Lang Chen², Melissa Mannion⁴, Kenneth G. Saag⁵, Jie Zhang⁶ and Jeffrey R. Curtis⁵, ¹Pediatric Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ²Division of Clinical Immunology & Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ³University of Alabama at Birmingham, Birmingham, AL, ⁴Pediatrics, University of Alabama at Birmingham, Birmingham, AL, ⁵Division Clinical Immunology & Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁶Epidemilogy, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: The comparative risk of infection with newer biologic agents, such as abatacept (ABA), in the treatment of juvenile idiopathic arthritis (JIA) has not been…
Abstract Number: 1673 • 2016 ACR/ARHP Annual Meeting
Characteristic Phenotypes of Peripheral T Cells and Efficacy of Biological Dmards in Patients with Psoriatic Arthritis
Ippei Miyagawa¹, Shingo Nakayamada², Satoshi Kubo³, Kazuhisa Nakano², Yusuke Miyazaki³, Maiko Yoshikawa⁴ and Yoshiya Tanaka⁵, ¹University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, ²First Department of Internal Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, ³The First Department of Internal Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, ⁴The First Department of Internal Medicine, University of Occupational and Environmental Health, Japan, Kitakyusyu, Japan, ⁵University of Occupational and Environmental Health, Kitakyushu, Japan
Background/Purpose: Biological DMARDs (bDMARDs) such as adalimumab (ADA), infliximab (IFX), ustekinumab (UST) and secukinumab (SEC) become available and efficacious in patients with psoriatic arthritis (PsA).…
Abstract Number: 2333 • 2016 ACR/ARHP Annual Meeting
Comparison of Clinical Outcomes of Total Ankle Arthroplasty Between Biologics and NON-Biologics Treatment Groups in Patients with Rheumatoid Arthritis
Makoto Hirao¹, Kosuke Ebina², Takaaki Noguchi³, Hideki Tsuboi⁴, Jun Hashimoto⁵ and Hideki Yoshikawa⁶, ¹Orthopaedic Surgery, Osaka University, Graduate School of Medicine, Suita, Japan, ²Orthopaedic Surgery, Osaka University Graduate School of Medicine, Osaka, Japan, ³Orthopaedic Surgery, Osaka University, Graduate School of Medicine, Osaka, Japan, ⁴Osaka Rosai Hospital, Sakai, Japan, ⁵Dept of Rheumatology, Osaka-Minami Medical Center, Kawachinagano City, Japan, ⁶Department of Orthopedics, Osaka University Graduate School of Medicine, Suita Osaka, Japan
Background/Purpose: In progress of medical treatment against rheumatoid arthritis (RA) disease activity using methotrexate (MTX) and/or biologics, we often see cases that require surgical intervention…
Abstract Number: 2656 • 2016 ACR/ARHP Annual Meeting
Resume of Biologic Therapy after Tuberculosis Infection in Patients with Inflammatory Arthropathies. Daily Clinical Practice Data from an Endemic Country
Liliana Uribe Botero¹, Margarita A Saldarriaga Alvarez¹, Natalia Duque Zapata¹, Johnny Urrego¹, Oscar Jair Felipe Diaz¹, Carmen Cerón², Alejandro Uribe¹, Luis Alonso Gonzalez^1,3 and José A. Gómez-Puerta¹, ¹Medicarte IPS, Medellín, Colombia, Medellín, Colombia, ²Medicarte IPS, Medellín, Colombia, ³Rheumatology Unit, Universidad de Antioquia, Medellin, Colombia
Background/Purpose: Long-term extension studies and observational drug registers mainly from Western countries or non-endemic areas have reported an increased risk of tuberculosis (TB) infection in…
Abstract Number: 626 • 2016 ACR/ARHP Annual Meeting
Switching Biologic Therapy in a Population of Rheumatoid Arthritis Patients
Branca Souza¹, Juliana Valim², Fernanda Chaer³, Fernanda Guimarães⁴ and Verônica Lima⁵, ¹Reumatologia, Irmandade da Santa Casa de Misericordia de São Paulo, São Paulo, Brazil, ²Rheumatology, Santa Casa de São Paulo, São Paulo, Brazil, ³Rheumatology, Irmandade da Santa Casa de São Paulo, São Paulo, Brazil, ⁴Rheumatology, Irmandade Santa Casa de Misericordia de São Paulo, São Paulo, Brazil, ⁵Rheumatology, Irmandade Santa Casa de São Paulo, São Paulo, Brazil
Background/Purpose: Evaluate the reason of exchange of biologic therapy in patients with rheumatoid arthritis and describe the frequency of remission or low activity, according to…
Abstract Number: 1674 • 2016 ACR/ARHP Annual Meeting
Do TNF Inhibitors Change the Progression of Sacroiliitis?
Deeba Minhas¹, MinJae Lee^2,3, Mohammad H. Rahbar³, Lianne S. Gensler⁴, John D. Reveille⁵ and Michael Weisman¹, ¹Rheumatology, Cedars-Sinai Medical Center, Los Angeles, CA, ²Medicine, University of Texas Health Science Center at Houston, Houston, TX, ³Biostatistics/Epidemiology/Research Design (BERD) Core | Center for Clinical and Translational Sciences, University of Texas-McGovern Medical School, Houston, TX, ⁴Medicine/Rheumatology, UCSF, San Francisco, CA, ⁵Rheumatology, University of Texas-McGovern Medical School, Houston, TX
Background/Purpose: Ankylosing spondylitis (AS) is a chronic inflammatory arthritis affecting the sacroiliac (SI) joints and spine causing structural changes seen on clinical radiography. Studies have…
Abstract Number: 2343 • 2016 ACR/ARHP Annual Meeting
A Phase 2, Multi-Center, Randomized, Double-Blind, Active-Controlled, Parallel Group Study to Evaluate the Safety and Dose Effectiveness of Intradermal Injections of Purified Apis Mellifera Toxin to Improve Pain and Physical Function in Patients with Osteoarthritis of the Knee
Douglas R. Schumacher¹, Anna Jakubowska² and Christopher M.H. Kim³, ¹Radiant Research, Columbus, OH, ²Apimeds, Inc., Jungwongu, Seongnam, Gyeonggido, Korea, The Republic of, ³CHA University, Bundanggu, Seongnam, Gyeongghido, Korea, The Republic of
Background/Purpose: This Phase 2a/b trial evaluated the safety and dose effectiveness of honeybee toxin (purified Apis melliferatoxin) injections to improve pain and physical function in…
Abstract Number: 2669 • 2016 ACR/ARHP Annual Meeting
Biological Treatments in Primary SjöGren Syndrome
Monica Fernandez Castro¹, Jose Luis Andreu², Carlos Sánchez-Piedra³, Víctor Martínez Taboada⁴, Alejandro Olivé⁵, José Rosas⁶, Raúl Menor Almagro⁷, Beatriz Rodriguez Lozano⁸, Angel Garcia-Aparicio⁹, Francisco Javier López Longo¹⁰, Sara Manrique-Arija¹¹, Jesus Alberto Garcia Vadillo¹², Susana Gil Barato¹³, Ruth Lopez Gonzalez¹⁴, Javier Narváez¹⁵, Carlos Galisteo¹⁶ and on behalf of Sjogren-SER project (GEEAS-SER), ¹Rheumatology, Hospital Infanta Sofía, Madrid, Spain, ²Rheumatology, Hospital Universitario Puerta de Hierro Majadahonda, Madrid, Spain, ³Unidad de Investigación de la Sociedad Española de Reumatología, Madrid, Spain, ⁴Rheumatology, Hospital Marqués de Valdecilla, Santander, Spain, ⁵Rheumatology, Hospital Universitario Germans Trias i Pujol, Barcelona, Spain, ⁶Rheumatology, Hospital Marina Baixa, Villajoyosa (Alicante), Spain, ⁷Rheumatology, Hospital General de Jerez de la Frontera, Jerez de la Frontera, Spain, ⁸Rheumatology, Hospital de Canarias, S/C Tenerife, Spain, ⁹Rheumatology, Hospital Virgen de la Salud, Toledo, Spain, ¹⁰Rheumatology, Hospital Gregorio Marañón, Madrid, Spain, ¹¹Rheumatology, Hospital Carlos Haya, Malaga, Spain, ¹²Rheumatology, Hospital La Princesa, Madrid, Spain, ¹³Rheumatology, Hospital General de Alicante, Alicante, Spain, ¹⁴Rheumatology, Hospital Virgen de la Concha, Salamanca, Spain, ¹⁵Rheumatology Department, Hospital Universitari de Bellvitge, L’Hospitalet de Llobregat, Spain, ¹⁶Rheumatology, Hospital Parc-Taulí, Sabadell, Spain
Background/Purpose: Primary Sjögren syndrome (pSS) is a systemic autoimmune disease involving mainly the exocrine glandular system. Nevertheless, its clinical spectrum includes the development of multiple…
Abstract Number: 628 • 2016 ACR/ARHP Annual Meeting
Analysis of Baseline Characteristics of Rheumatoid Arthritis Patients Treated with Abatacept Compared to Those Treated with Tumor Necrosis Factor Inhibitors in Clinical Practice
M. Victoria Hernández¹, Carlos Sánchez-Piedra², Juan D. Cañete¹, Fernando Sanchez-Alonso², Javier Manero³, Ana M. Ortiz Garcia⁴, Eva Pérez-Pampin⁵, Rosa Roselló⁶, Carlos Rodriguez-Lozano⁷, Raimon Sanmarti¹, Juan J. Gómez-Reino⁵ and BIOBADASER 2.0 Study Group, ¹Rheumatology Department, Hospital Clínic de Barcelona, Barcelona, Spain, ²Research Unit, Spanish Society of Rheumatology, Madrid, Spain, ³Rheumatology, Hospital Miguel Servet, Zaragoza, Spain, ⁴Rheumatology, Rheumatology Service, Hospital Universitario de La Princesa, IIS-IP, Madrid, Spain, ⁵Rheumatology, Hospital Clínico Universitario. Santiago de Compostela, Santiago de Compostela, Spain, ⁶Rheumatology, H San Jorge, Huesca, Spain, ⁷Rheumatology, Hospital de Gran Canaria Dr. Negrín, Las Palmas de Gran Canaria, Spain
Background/Purpose: Currently, the most widely used biological agents for rheumatoid arthritis (RA) patients are the inhibitors of the tumor necrosis factor (TNFi), although other biological…
Abstract Number: 1682 • 2016 ACR/ARHP Annual Meeting
Tnfα Inhibitors Are Associated with Reduced Progression of Carotid Atherosclerotic Plaques By Ultrasound and an Improvement in Aortic Arch Vascular Inflammation By 18-FDG PET/CT in Psoriasis and Psoriatic Arthritis Patients – a Prospective Study from Two Cohorts
Lihi Eder¹, Aditya Joshi², Vinod Chandran³, Amit Dey⁴, Richard J. Cook⁵, Abhishek Chaturvedi⁶, Dafna D. Gladman⁷ and Nehal Mehta⁸, ¹Medicine, University of Toronto, Women's College Hospital, Toronto, ON, Canada, ²National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, ³Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ⁴National Institutes of Health, Bethesda, MD, ⁵Department of Statistics and Actuarial Science, University of Waterloo, Waterloo, ON, Canada, ⁶National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, ⁷Rheumatology, Centre for Prognosis Studies in the Rheumatic Diseases, Toronto Western Hospital and University of Toronto, Toronto, ON, Canada, ⁸National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, MD
Background/Purpose: Psoriasis (PSO) and psoriatic arthritis (PsA) are chronic inflammatory diseases which are associated with increased cardiovascular (CV) diseases. Observational studies have found that TNFα…
Abstract Number: 2375 • 2016 ACR/ARHP Annual Meeting
Biologic Therapy Modifies Clinical and Laboratory Features of Macrophage Activation Syndrome Associated with Systemic Juvenile Idiopathic Arthritis
Grant Schulert¹, Francesca Minoia², John F. Bohnsack³, Randy Q. Cron⁴, Soah Hashad⁵, Isabelle Koné-Paut⁶, Mikhail Kostik⁷, Daniel J Lovell⁸, Despoina Maritsi⁹, Peter A. Nigrovic¹⁰, Priyankar Pal¹¹, Angelo Ravelli², Masaki Shimizu¹², Valda Stanevicha¹³, Bas Vastert¹⁴, Fabrizio De Benedetti¹⁵ and Alexei Grom¹⁶, ¹Pediatric Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ²Istituto Giannina Gaslini, Genoa, Italy, ³Division of Allergy, Immunology and Pediatric Rheumatology, University of Utah, Salt Lake City, UT, ⁴Pediatric Rheumatology, Children's Hospital of Alabama, Birmingham, AL, ⁵Tripoli Children's Hospital, Tripoli, Libya, ⁶Hopital Kremlin Bicetre, University of Paris SUD, Paris, France, ⁷Hospital Pediatrics, State Pediatric Medical University, Saint-Petersburg, Russia, ⁸PRCSG Cincinnati Children's Hospital Medical Center, Cinncinnati, OH, ⁹2nd Department of Academic Pediatrics, Athens Medical School, university of Athens, Athens, Greece, ¹⁰Rheumatology, Immunology, and Allergy, Brigham and Women’s Hospital, Boston, MA, ¹¹Institute of Child Health, Kolkata, India, ¹²Department of Pediatrics, School of Medicine, Institute of Medical, Pharmaceutical, and Health Sciences, Kanazawa University, Kanazawa, Japan, ¹³Pediatric cathedra, Riga Stradiņš University, Riga, Latvia, ¹⁴Wilhelmina Children's Hospital / UMC Utrecht, Utrecht, Netherlands, ¹⁵Division of Rheumatology, Ospedale Pediatrico Bambino Gesù IRCCS, Roma, Italy, Rome, Italy, ¹⁶Cincinnati Children's Hospital Medical Center, Cincinnati, OH
Background/Purpose: Macrophage activation syndrome (MAS) is a life-threatening episode of hyperinflammation and a substantial cause of morbidity and mortality in pediatric rheumatology. It occurs most…

« Previous Page
1
…
8
9
10
11
12
…
26
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.